Search Results
Nov 28, 2025, 05:09 ET Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
anti-drip design, delivering robust biosafety in demanding laboratory environments.High-Sensitivity NAT Reagents to Detect Low-Load InfectionsKHB's high-sensitivity NAT reagent complements Tianlong's automated platform, using qualitative real-time PCR in an all-in-one format that
More news about: Tianlong Science and Technology
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
investors.ReferencesAmin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying
More news about: Eisai Inc.
Nov 21, 2025, 13:30 ET Researchers Highlight Genetic Factors in Pediatric Brain and Spinal Cord Tumors
Institute.Corbett, RJ, Kaufman RS, et al. "Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors." Nat Comms. Online. Online November 21, 2025. DOI:10.1038/s41467-025-65190-4.About Children's Hospital of Philadelphia: A non-profit,
More news about: Children's Hospital of Philadelphia
Nov 20, 2025, 05:47 ET Viktig lansering från Merus Power: Det första nätbildande batterilagringssystemet i Norden
möjliggör exempelvis uppbyggnaden av ett nät efter ett totalavbrott och gör energilagret till en aktiv möjliggörare av nätstabilitet. Nätbildande innebär att ett energilager eller en annan kraftkälla inte enbart följer ett befintligt nät, utan själv kan etablera och upprätthålla
More news about: Merus Power Plc
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
doi:10.7150/jca.75622. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-561. doi:10.1038/nrclinonc.2017.71. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757,
More news about: Amgen
Nov 19, 2025, 15:30 ET With a $2.5B Valuation, Function Becomes the New Standard for Health and Launches Medical Intelligence Lab
globally. The round brings the company's valuation to $2.5 billion, and supports its Medical Intelligence efforts and accelerating growth. Investors include Nat Friedman and Daniel Gross' NFDG, a16z, Aglaé Ventures, Alumni Ventures, NBA's Allen Crabbe, Roku founder Anthony Wood, Battery Ventures, Blake &
More news about: Function Health
Nov 19, 2025, 07:00 ET Thailand Freighter Pattaya Airways Joins WebCargo by Freightos Platform, Expanding Digital Air Cargo Access in Southeast Asia
customers." "For us, this isn't just about going digital — it's about keeping up with how freight really moves today," said Nat Boonyavichkanont, Chief Executive Officer of Pattaya Airways Company, Ltd. "Pattaya Airways is proud to collaborate with WebCargo by
More news about: Freightos
Nov 18, 2025, 08:00 ET Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi: 10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying
More news about: Eisai Inc.
Nov 17, 2025, 10:24 ET Frentree Partners with AccuKnox to Expand Zero Trust CNAPP Security in South Korea
platform stands out for its depth and scalability with advanced AI security. "South Korea is a highly sophisticated and discerning market," said Nat Natraj, CEO, AccuKnox. "Frentree has immense expertise in Cloud Security, we are very excited about our partnership with Frentree and serving clients
More news about: AccuKnox Inc.
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
doi:10.1080/03007995.2016.12086432 Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy – clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519-539.3 Epworth Sleepiness Scale: 8-item self-administered questionnaire that measures severity of excessive
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
doi:10.1080/03007995.2016.12086432 Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy – clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519-539.3 Epworth Sleepiness Scale: 8-item self-administered questionnaire that measures severity of excessive
More news about: Alkermes plc
Nov 11, 2025, 08:30 ET Exploring Polycystic Kidney Disease Clinical Trials and New Treatments, Upcoming Webinar Hosted by Xtalks
Aydogan Balaban, H.Ö., Arjune, S., Grundmann, F. et al. Developing serum proteomics based prediction models of disease progression in ADPKD. Nat Commun 16, 6646 (2025).
More news about: Xtalks
Nov 10, 2025, 08:00 ET Johnson & Johnson lança plataforma VARIPULSE™ no Brasil e avança no tratamento da fibrilação atrial
iii Anter, E., Mansour, M., Nair, D.G. et al. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med 30, 2303–2310 (2024). https://doi.org/10.1038/s41591-024-03022-6 pg 2 iv Reddy
More news about: Johnson & Johnson MedTech
Nov 07, 2025, 08:30 ET FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
Froyen, G, Maclachlan, K.H, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021;12(1861). doi:10.1038/s41467-021-22140-03 Maura, F, Bergsagel PL. Targeting the Tumor and the Immune System in Smoldering
More news about: Halozyme Therapeutics, Inc.
Nov 07, 2025, 03:07 ET San Antonio Hosts Inaugural NatGas To Power Forum on Fueling AI Data Centers with Natural Gas
https://www.ldcgasforums.com/ngtp/. About the LDC Gas Forums (4), Gulf Coast Energy Forum, and Nat Gas to Power Forum The LDC Gas Forum series consists of six annual events, each focused on a key natural
More news about: LDC Gas Forums
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Froyen, G, Maclachlan, K.H, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021;12(1861). doi:10.1038/s41467-021-22140-04 Maura, F, Bergsagel PL. Targeting the Tumor and the Immune System in Smoldering
More news about: Johnson & Johnson
Nov 06, 2025, 07:00 ET Kimbell Royalty Partners Announces Third Quarter 2025 Results
Nat Gas
More news about: Kimbell Royalty Partners, LP
Nov 05, 2025, 11:36 ET Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
here. References 1. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. 2. Servais A, et al. Kidney Int. 2012;82(4):454-464. 3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.
More news about: Swedish Orphan Biovitrum AB
Nov 04, 2025, 15:00 ET Best VPN for Android (2025): NordVPN Recognized for Speed and Security by Expert Consumers
IKEv2/IPsec, to balance high performance with strong security. NordLynx, built on the advanced WireGuard® framework, uses a double Network Address Translation (NAT) system to protect privacy while maintaining fast and efficient connections. Independent performance tests have placed NordVPN
More news about: ExpertConsumers.org
Nov 04, 2025, 13:14 ET INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
October 2025.4 Demarest, J.F., Draghia-Akli, R., Cihlar, T. et al. Antiviral target compound profile for pandemic preparedness. Nat Rev Drug Discov 24, 151–152 (2025).
More news about: INTREPID Alliance
Nov 04, 2025, 12:55 ET INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
October 2025.4 Demarest, J.F., Draghia-Akli, R., Cihlar, T. et al. Antiviral target compound profile for pandemic preparedness. Nat Rev Drug Discov 24, 151–152 (2025).
More news about: INTREPID Alliance
Oct 31, 2025, 13:04 ET BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
[abstract]. Skin. 2024,8(6):s473. EADV. 7925. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.
More news about: UCB
Oct 27, 2025, 10:21 ET Gold Holds Above $4,100 as Miners Capture Expanding Profit Margins
approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions
More news about: USA News Group
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Coates LC, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79. Garcia-Magallón B et al. Is the new ASDAS nomenclature in agreement with therapeutic decision
More news about: UCB
Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
antibodies in participants treated with nipocalimab. 2024 Sep.4 IMAAVYTM U.S. Prescribing Information.5 Nat Rev Rheumatol 20, 158–169 (2024).
More news about: Johnson & Johnson